What is TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE used for?

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE (brand name Trandolapril and Verapamil Hydrochloride) is a ACE Inhibitor indicated for consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis.

How does TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE work?

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE works through the following mechanism: ACE Inhibitor agent.

What are the most common side effects of TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE?

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Is TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE the same as Trandolapril and Verapamil Hydrochloride?

Trandolapril and Verapamil Hydrochloride is a brand name for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

ACE Inhibitor

Brand names: Trandolapril and Verapamil Hydrochloride

Oral

Mechanism of Action

ACE Inhibitor agent

Indications

consideration should be given to the fact that an angiotensin converting enzyme inhibitor

captopril

has caused agranulocytosis

particularly in patients with renal impairment or collagen vascular disease

and that available data are insufficient to show that trandolapril does not have similar risk (see WARNINGS - Neutropenia/Agranulocytosis ).

Contraindications

• Lown-Ganong-Levine syndromes) (see WARNINGS ). 6. Patients taking flibanserin (see PRECAUTIONS - Drug Interactions ). Because of the trandolapril component
• sacubitril). Do not administer trandolapril and verapamil hydrochloride extended-release tablets within 36 hours of switching to or from sacubitril/valsartan
• a neprilysin inhibitor (see WARNINGS ).

FDA Warnings

WARNING: FETAL TOXICITY • When pregnancy is detected, discontinue trandolapril and verapamil hydrochloride extended-release tablets as soon as possible
• Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (see WARNINGS: Fetal Toxicity )

Known Side Effects

12 documented side effects by frequency

Shortness of Breath

1-10%

Fatigue

1-10%

Dizziness

1-10%

Diarrhea

1-10%

Weakness

1-10%

Cough

1-10%

Drug Not Working

1-10%

Nausea

1-10%

Low Blood Pressure

1-10%

High Blood Pressure

1-10%

Joint Pain

0.1-1%

Headache

0.1-1%

Community Discussions

No community discussions found for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE yet.

Primary sources

Every figure on this page links back to its primary source. See data sources for full provenance.

DailyMed FDA label search → TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE openFDA label JSON → TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE FAERS adverse-event reports → TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE ClinicalTrials.gov → completed Phase 2+ trials of TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

Compare With

8 available comparisons

Formulations

Dosage Forms

Tablet

Route

Oral